Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System. The Circular External Fixation System, expected to commercially launch in early 2022, will...
ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting...
Paragon 28, Inc. Increases its Robust Hindfoot Fusion Plating Offering, Launching the Silverback™ Span Plating System Paragon 28® is pleased to announce the launch of its Silverback™ Span Plating System, which was specifically designed to be used in combination with a structural allograft or a titanium cage in cases where a significant void is present...
Paragon 28®, Inc. Increases its Robust Hindfoot Fusion Plating Offering, Launching the Silverback™ Straddle Plating System ENGLEWOOD, Colo., Aug. 19, 2021 /PRNewswire/ — Paragon 28® is pleased to announce the launch of its Silverback™ Straddle Plating System designed to supplement the Phantom® Hindfoot TTC Fusion Nail allowing surgeons to create a plate and nail construct for tibiotalocalcaneal...
Paragon 28, Inc. Names Scott Drake to its Board of Directors ENGLEWOOD, Colo., Aug. 10, 2021 /PRNewswire/ — Paragon 28, Inc. announced today that Scott Drake has joined its Board of Directors. “Scott is an accomplished leader in the medical technology space, possessing both outstanding strategic vision and operational know-how,” said Albert DaCosta, Co-Founder, President, and Chief Executive Officer of Paragon...
DENVER, June 1, 2021 /PRNewswire/ — Paragon 28, Inc., a market-leading orthopedic medical device company focused exclusively on the foot-and-ankle, today announced that the Company has acquired the product lines of Additive Orthopaedics (“Additive”). The Additive 3D-printed Patient Specific Talus Spacer was approved on February 17, 2021 by the US Food and Drug Administration (“FDA”) and is the first...
ENGLWOOD, Colo., May 20, 2021 /PRNewswire/ — Paragon 28 is pleased to announce the launch of the BEAST™ Injectable Putty, BEAST PLUS™, and BEAST™ Osteobiologic Sponge (BOB™)! All three grafts have a high osteoinductive potential, excellent handling characteristics, and are processed using a proprietary method which ensures preservation of native bone morphogenic proteins (BMP), notably 2,...
DENVER, May 17, 2021 /PRNewswire/ — Paragon 28, Inc. a market leading orthopedic medical device company focused exclusively on the foot and ankle, today announced that the Company has entered into a credit facility with MidCap Financial (“MidCap”) providing Paragon 28 access up to $70 million in total credit. Read the full article here.
ENGLEWOOD, Colo., May 12, 2021 /PRNewswire/ — Paragon 28, Inc. continues to revolutionize the Orthopedic Total Ankle Joint Replacement (TAR) market by successfully introducing the FasTrac™ Distal Tibia Alignment System, featuring proprietary laser technology developed to provide a precise visual reference point during component alignment, a critical step in establishing optimal implant placement during TAR procedures....
ENGLEWOOD, Colo., May 4, 2021 /PRNewswire/ — Paragon 28, Inc. unveils the highly anticipated MAVEN™ PSI System, a platform technology thoughtfully designed to expedite accurate positioning of the APEX 3D™ Total Ankle Replacement System. MAVEN PSI advances patient-specific technologies with anatomical design features promoting alignment accuracy, stability, and ideal implant placement. MAVEN PSI is compatible...
The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.
© 2024 Paragon 28, Inc.
